These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8242797)

  • 1. Activation of the complement system by the capsule of Cryptococcus neoformans.
    Kozel TR
    Curr Top Med Mycol; 1993; 5():1-26. PubMed ID: 8242797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opsonization and phagocytosis of Cryptococcus neoformans.
    Kozel TR
    Arch Med Res; 1993; 24(3):211-8. PubMed ID: 8298269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans.
    Kozel TR; Wilson MA; Murphy JW
    Infect Immun; 1991 Sep; 59(9):3101-10. PubMed ID: 1831795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance.
    Zaragoza O; Casadevall A
    Cell Microbiol; 2006 Dec; 8(12):1862-76. PubMed ID: 16824038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
    Kozel TR; Wilson MA; Pfrommer GS; Schlageter AM
    Infect Immun; 1989 Jul; 57(7):1922-7. PubMed ID: 2525113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast.
    Kozel TR; Pfrommer GS
    Infect Immun; 1986 Apr; 52(1):1-5. PubMed ID: 3514450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement.
    Verbrugh HA; Peterson PK; Nguyen BY; Sisson SP; Kim Y
    J Immunol; 1982 Oct; 129(4):1681-7. PubMed ID: 7108223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection.
    Diamond RD; May JE; Kane MA; Frank MM; Bennett JE
    J Immunol; 1974 Jun; 112(6):2260-70. PubMed ID: 4596700
    [No Abstract]   [Full Text] [Related]  

  • 9. The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions.
    Zaragoza O; Taborda CP; Casadevall A
    Eur J Immunol; 2003 Jul; 33(7):1957-67. PubMed ID: 12884862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3.
    Kozel TR; Pfrommer GS; Guerlain AS; Highison BA; Highison GJ
    Infect Immun; 1988 Nov; 56(11):2794-800. PubMed ID: 3049374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans.
    Laxalt KA; Kozel TR
    Infect Immun; 1979 Nov; 26(2):435-40. PubMed ID: 397927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CR3-dependent phagocytosis by murine macrophages: different cytokines regulate ingestion of a defined CR3 ligand and complement-opsonized Cryptococcus neoformans.
    Cross CE; Collins HL; Bancroft GJ
    Immunology; 1997 Jun; 91(2):289-96. PubMed ID: 9227330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycobacterium tuberculosis and the complement system.
    Schlesinger LS
    Trends Microbiol; 1998 Feb; 6(2):47-9; discussion 49-50. PubMed ID: 9507637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways.
    Mershon-Shier KL; Vasuthasawat A; Takahashi K; Morrison SL; Beenhouwer DO
    Mol Immunol; 2011 Sep; 48(15-16):2009-18. PubMed ID: 21723612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Physiopathology of meningoencephalitis caused by Cryptococcus neoformans].
    Neuville S; Dromer F; Chrétien F; Gray F; Lortholary O
    Ann Med Interne (Paris); 2002 Sep; 153(5):323-8. PubMed ID: 12442078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages.
    Kozel TR; Gotschlich EC
    J Immunol; 1982 Oct; 129(4):1675-80. PubMed ID: 7050244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of humoral factors in host resistance to the Bacteroides fragilis group.
    Bjornson AB
    Rev Infect Dis; 1990; 12 Suppl 2():S161-8. PubMed ID: 2406868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subversion of complement activation at the bacterial surface promotes serum resistance and opsonophagocytosis of Francisella tularensis.
    Ben Nasr A; Klimpel GR
    J Leukoc Biol; 2008 Jul; 84(1):77-85. PubMed ID: 18430786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the capsule in phagocytosis of Cryptococcus neoformans.
    Kozel TR; Pfrommer GS; Guerlain AS; Highison BA; Highison GJ
    Rev Infect Dis; 1988; 10 Suppl 2():S436-9. PubMed ID: 3055212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation, binding, and processing of complement component 3 (C3) by Blastomyces dermatitidis.
    Zhang MX; Klein B
    Infect Immun; 1997 May; 65(5):1849-55. PubMed ID: 9125571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.